SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is driving significant community engagement as holders rally behind an active developer to push for organic growth, increased visibility on trading platforms, and a long-term vision of sustained market cap expansion. The conversation is currently dominated by enthusiasts coordinating raids and social media activity to fuel a potential breakout, while simultaneously addressing skepticism from market critics.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as community members highlight its low market cap and ultra-limited circulating supply as potential catalysts for significant upside. Traders are actively debating the token's long-term potential compared to other projects, with many focused on accumulation and the impact that increased trading volume could have on its price action.

Bitcoin SV (BSV) emerged following a hard fork of the Bitcoin Cash (BCH) blockchain in 2018, which had in turn forked from the BTC blockchain a year earlier. The goal of Bitcoin SV is to fulfil the original vision of the Bitcoin protocol and design as described in Satoshi Nakamoto’s white paper, early Bitcoin client software and known Satoshi writings. BSV aims to offer scalability and stability in line with the original description of Bitcoin as a peer-to-peer electronic cash system, as well as deliver a distributed data network that can support enterprise-level advanced blockchain applications. To this end, it has removed artificial block size limits and re-enabled Script commands and other technical capabilities which had been historically disabled or restricted by the protocol developers of the BTC blockchain. This allows the network to process tens of thousands of transactions per second while maintaining extremely low transaction fees for micropayments, in addition to offering advanced capabilities such as tokens, smart contracts, computation and other data use cases. The BSV network is unique in its capacity for unbounded on-chain scaling while also being more aligned with the original design of Bitcoin than any other blockchain.

Bitcoin SV

Bitcoin SV is currently generating intense community debate as participants weigh the implications of the ongoing legal challenges regarding Craig Wright's identity and his association with the project. While some investors remain focused on the potential of the network's high transaction capacity and its original white paper design, others are actively reacting to price volatility and the broader sentiment surrounding the asset's delisting from major platforms.

Dunald Dump

The community is actively discussing the rapid momentum and viral potential surrounding this new meme coin, focusing on its market capitalization growth and speculative entry opportunities.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a major point of discussion due to a mix of aggressive community speculation regarding a potential recovery and significant debate over recent leadership shifts within the foundation. Traders are actively analyzing the token's technical positioning and its long-term viability, with many members emphasizing the network's quantum-resistant architecture and ongoing institutional adoption as catalysts for a future rebound.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending as the community closely watches for upcoming earnings and potential catalysts, with active debate focusing on heavy call option volume, high short interest, and persistent rumors of a potential merger or acquisition. Traders remain divided, with some positioning for a short squeeze fueled by significant institutional partnerships, while others express caution due to ongoing concerns regarding recent leadership transitions and execution.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and community division as traders weigh historically high valuations against continued AI infrastructure demand. While some investors are betting on further upside through aggressive call buying, others are warning of a crowded trade and potential bubble risks, fueling a debate over whether the sector is poised for a major correction or further growth.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Fan Tokens allow fans across multiple sports verticals to exercise their share of influence within their favourite teams/leagues/clubs. Through Socios.com, fans are empowered to participate in certain club decisions, for example, choosing a goal celebration song in a football stadium, choosing which fighters should go head to head in MMA, and more. Thanks to Fan Tokens, holders receive access to once-in-a-lifetime experiences such as player meet and greets, training day events &amp; much much more.  The growing list of partnerships launching their Fan Tokens on the Socios.com platform includes some of the biggest sporting organizations in the world such as FC Barcelona, Inter Milan, AC Milan, Manchester City, UFC, ROUSH Fenway Racing, Aston Martin, just to name a few.

Italian National Football Team Fan Token

ITA is currently trending as investors navigate extreme geopolitical volatility stemming from direct military escalations in the Middle East, leading to intense debates about the sustainability of a massive defense spending surge. Market participants are closely watching how persistent conflict and potential shifts in government budget priorities will impact the sector's long-term momentum versus its recent high valuation.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis AG

Novartis is trending as investors digest the acquisition of Anthos Therapeutics and the company's aggressive $23 billion commitment to expand its U.S. manufacturing and R&D infrastructure. Community sentiment remains focused on Novartis's strategic pivot toward high-growth oncology and cardiovascular pipelines as it navigates the competitive landscape for blockbusters like Pluvicto and Fabhalta.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alpha Cognition (NASDAQ:ACOG) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered Alpha Cognition from a "hold" rating to a "sell" rating in a report on Saturday...

Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?

Alpha Cognition Inc. (ACOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,589,099 on...

Alpha Cognition (ACOG) Q4 2025 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Alpha Cognition (NASDAQ:ACOG) Posts Earnings Results, Misses Estimates By $0.03 EPS

Alpha Cognition (NASDAQ:ACOG - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus...

Alpha Cognition Q4 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) executives told investors the company is seeing continued sales growth and what it described as accelerating, durable adoption following the commercial launch of...

Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue Estimates

Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -11.11% and -12.72%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Alpha Cognition Inc. (ACOG: NASDAQ) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported...

Alpha Cognition (ACOG) to Release Earnings on Monday

Alpha Cognition (NASDAQ:ACOG) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-alpha-cognition-inc-stock...

Alpha Cognition Inc. (NASDAQ:ACOG) Sees Significant Growth in Short Interest

Alpha Cognition Inc. (NASDAQ:ACOG - Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 317,725 shares, a growth of...

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

Alpha Cognition Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$5.98
Prev Close	$5.96
Open	$5.91
Dividend Yield	0.00%
50-Day Moving Average	$5.58
Beta	0.83
Avg. Volume	57,161.50
PE Ratio	-5.11

52-Week High	$11.54
52-Week Low	$3.75
Market Capitalization	$130.21M
EPS (Annual)	-$1.18
Price to Book	2.08
Revenue Per Employee	$143,947.54

ACOG
Alpha Cognition Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACOG News

ACOGAlpha Cognition Inc